New peer-reviewed research confirms that myopia control gains with CooperVision’s MiSight 1 day* dual-focus soft contact lenses are sustained after treatment, with post-treatment eye growth aligning with that of untreated, age-matched populations.
Publication of the seven-year study, in Optometry and Vision Science,1 further validates the use of virtual control groups for rigorous myopia control research while further strengthening support for treating children with MiSight 1 day.
The study followed subjects who had completed the six-year MiSight 1 day clinical trial – both the cohort who wore MiSight 1 day for all six years and the cohort who switched from the single vision to the MiSight 1 day lens for the final three years – for an additional year following treatment cessation. The results showed that children retained the benefits of myopia control without experiencing accelerated myopia progression post-treatment.
“Eye care professionals (ECPs) have embraced the importance of myopia control in children, and we are starting to see this reflected in prescribing behaviour around the world,” said Paul Chamberlain, Senior Director of Research Programs at CooperVision and the paper’s lead author.
The results showed that children retained the benefits of myopia control without experiencing accelerated myopia progression post-treatment
“To turn the tide on childhood myopia, ECPs must be confident in an intervention that not only slows progression†2 but makes long-term treatment worthwhile.
“MiSight 1 day clearly demonstrates these benefits, allowing ECPs to prescribe with confidence for both immediate and lasting impact.”
By using virtual control groups based on myopic children of the same age as those observed in year seven of this study, the new paper also provides the most robust validation to date of this model for assessing long-term myopia control outcomes. Investigators applied the model to the study’s preliminary outcomes data, first shared in 2021, and subsequently found their initial conclusions to be highly accurate.
The seven-year publication marks the final chapter in a trilogy of landmark publications on the study, joining the widely-cited three-year and six-year results,2,3 all of which are published in Optometry and Vision Science, the journal of the American Academy of Optometry.
‘Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens’1 is now accessible via Open Access.
Notes
* Regulatory indications of and access to interventions for slowing myopia progression vary by country. CooperVision does not endorse off-label prescribing.
† Compared to single vision lens, no clinically meaningful change in refractive error (-0.25D or less from baseline). Fitted at 8–12 years of age.
References
1 Chamberlain P, Hammond DS, Young G, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. Optom and Vis Sci. 2025 Mar 25. doi: 10.1097/OPX.0000000000002244. Epub ahead of print.
2. Chamberlain P, Peixoto-de-Matos SC, Young G, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019 Aug;96(8):556-567. doi: 10.1097/OPX.0000000000001410.
3. Chamberlain P, Bradley A, Young G, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: A 6-year multicenter clinical trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212. doi: 10.1097/OPX.0000000000001873.
